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Smnmary: We describe a gas-liquid Chromatographie method, using a nitrogen-specific detector, which is
suitable for the simultaneous quantitation of clobazam and its main metabolite N-demethyl clobazam in the
serum of epileptic patients treated with other anticonvulsant co-medication. Flunitrazepam (internal Standard)
is added to the sample and after extraction with a toluene/ethyl acetate mixture (3 + l by vol), the organic
extract is evaporated and the residue is reconstituted in a small volume of solvent and chromatographed on
a 3% SP2250 column. The sensitivity limits are about 2 to 5 g per liter of original sample.
Bestimmung von Clobazepam und seines N-Demethyl-Metaboliten im Serum von Epileptikern
Zusammenfassung: Wir beschreiben eine gaschromatographische Methode mit Stickstoff-spezifischer Detek-
tion zur gleichzeitigen quantitativen Bestimmung von Clobazepam und seines Hauptmetaboliten N-Deme-
thylclobazepam im Serum von Epileptikern, die zugleich mit anderen Antikonvulsiva behandelt wurden.
Fliiniträzepam wird als interner Standard zur Probe hinzugefügt. Nach Extraktion mit Toluol/Ethylacetat
(Volumina, 3 + 1) wird die organische Phase zur Trockne gebracht. Der Rückstand wird in einem kleinen
Volumen Lösungsmittel aufgenommen und an einer 3% SP 2250-Säule chromatographiert. Die Empfindlich-
keit Hegt bei 2—5 g/l Ausgangsprobe.
p uc on
 to t^e electron capture detectors because of the low
Clobazam, a 1,5-benzodiazepine, is marketed in sev- concentration of clobazam in serum. The gas-liquid
eral European countries äs an änxiolytic. Its antiepi- Chromatographie method described for the determi-
leptic properties have recently been documented in nation of clobazam and its major metabolite, N-
animals (l, 2) and in man (3, 4). For the quantitation demethyl clobazam, uses diazepam äs internal stan-
of clobazam in biological fluids, several HPLC (5) dard (6). When clobazam äs an antiepileptic agent
and gas-liquid Chromatographie methods (6—9) have was used in association with other anticonvulsants
been published. Gas-liquid chromatography is a valu- (e. g. phenobarbital, phenytoin, carbamazepine.. .),
able tool in therapeutic drug level monitoring because we observed a peak that coelutes with diazepam in
of its versatility in qualitative and quantitative analy- the serum of patients with phenytoin co-medication.
sis of a wide variety of drugs, Moreover, for routine Our purpose was to develop a simple and fast method
determinations in a clinical laboratory, gas-liquid for the determination of clobazam and N-demethyl
chromatography with a nitrogen-specific deteetor is clobazam that is fully specific in the presence of other
preferred to the usual flame ionization detector and anticonvulsant drugs.
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Materials and Methods
Equipment
A 3920B gas Chromatograph equipped with glass-lined heated
injector and detector jets was used (Perkin Eimer Corp., Nor-
walk, CT 06856), the chromatography glass cohimn was a 2 m
χ 2 mm 3% SP 2250 on 100/120 mesh Supelcoport (packing
1878, Supelco Bellefonte Pa.) plugged with glass wool treated
with phosphoric acid.
Blood collection tubes
Evacuated blood collection tubes were used: Venojet red stop-
per tube (Kimble-Terumo Inc., Elkton, MD 21921 exp. 3-87),
Vacutainer tubes-red Stopper (Becton Dickinson Rutherford,
NJ 07070 lots 4Z019 and 6430 4W022 exp. 12-86, respective-
Reagents and Standards
Ethyl acetate was glass distilled (Burdick & Jackson, Muskegon
MI 49442). Toluene was p. a. grade (Merck, Dannstadt,
F. R. G.). Clobazam and N-demethyl clobazam were kindly
supplied by Hoechst Aktiengesellschaft (6230 Frankfurt, Main
80). Flunitrazepam was obtained s a gift from Hoffmann-La
R che (Inc. Nutley, NJ 07110). Stock Standards: these were
prepared in ethyl acetate to obtain a concentration of 100 mg/1
for clobazam, N-demethyl clobazam and flunitrazepam.
Working Standards: these were prepared in ethyl acetate in the
r nge 10-150 ng/1 (clobazam) and 50-450 ng/1 (N-demethyl
clobazam.
Internal Standard Solutions: this was prepared in ethyl acetate
to give a concentration of 200 μg/l.
Extraction solvent: toluene/ethyl acetate (3 -l· l by vol).
Procedure
Column preparation: the column was conditioned at 300 °C for
24 h with a nitrogen flow rate of 30 ml/min. At the end, it was
primed by injecting 50 μg egg lecithin in benzene several times.
The use of this phospholipid s a priming agent gives a greater
peak resolution. At the beginning of each working day 50 μg
of lecithin three times were injected to prime the column.
Chromatographie conditions: oven temperature, isothermal
280 °C; injection port temperature, 350 °C; interface tempera-
ture, 325 °C; nitrogen flow rate, 30 ml/min. Detector nitrogen
mode: hydrogen flow rate, 4 ml/min; air flow rate, 60 ml/min;
detector current bead setting, 5.4; attenuation, l χ 32.
Determination of clobazam and N-demethyl clobazam: internal
Standard (500 μΐ) is added to a glass stoppered centrifuge tube,
then evaporated to dryness at 40 °C under mildly reduced
pressure. Serum (500 μΐ) is then added and mixed with vortexing
for 30 s. Extraction solvent (5 ml) is added and after mixing
(vprtex) for 15 min, the tube Contents are centrifuged at 5000
min"1 for 5min; the upper organic layer is decanted and
evaporated to dryness. Then the residue is dissolved in ethyl
acetate (50 μΐ) and 2.5 to 5.0 μΐ are injected into the Chromato-
graph. Quantification is based on the peak-height ratio of the
analyte to the internal Standard.
Results
Chromatograms
Figure l shows a typical chromatogram obtained by
the reported procedure from extracts of:
a) serum blank;
b) serum from a patient who was t king phenytoin,
phenobarbital and primidone s anticonvulsant; and
c) a serum sample from a patient who was t king
clobazam together with phenytoin, phenobarbital
and primidone.
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Chromatograms after extraction from serum with tolu-
ene/ethyl acetate (3/1 by vol), containing flunitrazepam
s internal Standard.
a) Extract of serum blank.
b) Extract of serum of a patient receiving phenobarbi-
tal, phenytoin and primidone s anticonvulsant.
c) Extract of serum of a patient receiving clobazam
together with phenobarbital, phenytoin and primidone.
The peaks shown are:
1) peak caused by the comedication with phenytoin,
2) clobazam (122 ng/1),
3) flunitrazepam,
4) N-demethyl clobazam (290 ng/1).
Linearity
We investigated the linearity of the peak-height ratios
versus serum drug concentrations (fig. 2) in the fol-
lowing ranges: 10 — 150 ng/1 for clobazam and
50—450 ng/1 for N-demethyl clobazam. The results
obtained by using a linear regression analysis were:
clobazam:
slope = 0.009 y-intercept = 0.012 r = 1.00
N-demethyl clobazam:
slope = 0.003 y-intercept = 0.000 r = 0.999
Precision
The precision of the method was determined by assay-
ing serum sainples wich contained known quantities
of the dr gs. As shown in table l withi -day precision
ranged from 1.4 to 6.8, between-day precision ranged
from 5.7 to 7.1 and, run-to-run precision between 3.8
and 4.3.
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Tab. 2. Relative retention times (internal Standard = 1.000.
Drug Relative retention time
100 200 300
c [ng/l]
400 500
Fig. 2. Peak height ratio of clobazam (χ) and N-demethyl
clobazam (D) to internal Standard vs clobazam and N-
demethyl clobazam concentrations in serum. The regres-
sion equation for clobazam was: y = 0.009 χ +0.012,
for N-demethyl clobazam it was: y = 0.003 χ + 0.000.
Tab. l. Precision for simultaneous determination of drugs in
serum.
f Drug
l|
K
i
t
|
t
Clobazam N-demethyl
ciooazam
Within-day
(n = 14)
Between-day
(n =
Run
10)
to run
Mean
(ng/l)
13
32
114
183
235
94
99
CV
(%)
4.4
4.2
2.9
1.4
6.3
7.0
3.8
Mean
(ng/l)
57
112
302
459
758
251
381
CV
(%)
6.8
4.9
3.9
4.4
5.7
7.1
4.3
Recovery
We detennined the analytical recovery of the assayed
drugs from serum by comparing the peak-height ra-
tios of extracted samples and internal Standard with
those of equivalent amounts of drugs and internal
Standard chromatographed directly. Recoveries were
95%.
Sensitivity
The lowest concentration of clobazam and N-deme-
thyl clobazam detectable in serum, defined s a signal
to npise r tip of 3, was 2 to 5 μg/l of the original
sample "when l ml serum was extracted.
Interferences
T ble 2 shpws the retention time of the drugs checked
for potential interference relative to the internal stan-
ki dard. None of these drugs cpelutes with clobazam,
'V· N-demethyl clobazam or internal Standard.
" "i The tubes used for blood collection (see Materials and
Ί! Methods) contain no contaminants that can affect the
;
 M analysis of the tested drugs.
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Carbamazepine
Phenobarbital
Nortriptyline
Amitriptyline
Nomifensine
Doxepine
Demethyl imipramine
Medazepam
Maprotyline
Mianserine
Clomipramine
Primidone
Phenytoin
Diazepam
Chlordiazepoxide
Clobazam
Flurazepam
N-demethyl clobazam
Bromazepam
Clonazepam
0.17
0.17
0.20
0.23
0.26
0.26
0.28
0.33
0.36
0.36
0.40
0.51
0.56
0.58
0.81
0.88
1.16
1.24
1.31
2.26
Studies with patient samples
To assess the performance of the procedure under
routine conditions, we detennined clobazam and N-
demethyl clobazam in the serum of 25 epileptic
patients in a dosage r nge of 0.5 to 1.5 mg/kg body
weight and a variety of co-medication. We measured
clobazam levels of 20 to 260 ng/l, and N-demethyl
clobazam levels of 200 to 11000 ng/l.
Discussion
The method we present ses an internal Standard of
similar chemical structure to clobazam and has the
advantage over the published gas-liquid Chromato-
graphie method that it permits quantitation of cloba-
zam and N-demethyl clobazam in the serum of epilep-
tic patients with concurrent administration of cloba-
zam and other antiepileptic drugs.
The method used is a single neutral extraction from
serum, followed by evaporation of the organic solvent
and injection of the redissolved residue directly into
the Chromatograph. The blank serum samples are
free of contaminants in the areas corresponding to
the retention time of clobazam, N-demethyl clobazam
and internal Standard. The patient results obtained
agree with those of other authors with respect to the
large clearance of clobazam by hepatic demethylation
(10), yielding the metabolic product N-demethyl clo-
bazam. Chronic treatment with clobazam leads to an
accumulation of very high values of serum N-deme-
thyl clobazam, and under these conditions its concen-
tration can be estimated by the use of the same
internal Standard with appropriate modification of
the calibration curve.
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